Completed PHASE3 INTERVENTIONAL 4-arm NCT01206972

Dose-confirmatory Bridging Study in Total Knee Replacement

Randomized, Double-blind, Parallel-group, Active-controlled, Dose-confirmatory Bridging Study of Rivaroxaban (BAY59-7939) 5 to 10 mg Once-daily Regimen With a Reference Drug of Enoxaparin in the Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement

Sponsor: Bayer

Conditions Venous Thromboembolism

Interventions Enoxaparin Rivaroxaban (BAY59-7939)

Updated 7 times since 2017 Last updated: Jan 17, 2017 Started: Oct 31, 2010 Primary completion: May 31, 2011 Completion: Jun 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Venous Thromboembolism and is currently completed. Bayer leads this study, which shows 7 recorded versions since 2010 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Oct 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bayer
Janssen Scientific Affairs, LLC

Data source: Bayer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adachi City, Japan , Asahikawa, Japan , Fukuoka, Japan , Hakodate, Japan , Hirakata, Japan , Iida, Japan , Izumi, Japan , Izumisano, Japan , Kakogawa, Japan , Kawanuma, Japan and 20 more locations